Prognostic analysis of single-agent olaparib or combination cediranib and olaparib for platinum sensitive recurrent ovarian cancer: overall survival outcomes from NRG-GY004

Gynecol Pelvic Med. 2024 Sep 9:8:29. doi: 10.21037/gpm-24-20. eCollection 2025.

Authors

Yusuke Taira¹, Wataru Kudaka¹, Tomoko Nakamoto¹, Yoshihisa Arakaki¹, Yuko Shimoji¹, Natsuki Tamashiro¹, Masayuki Sekine¹

Affiliation

¹ Department of Obstetrics and Gynecology, Graduate School of Medical Science University of the Ryukyus, Okinawa, Japan.

No abstract available

Keywords: Olaparib; cediranib; platinum sensitive; recurrent ovarian cancer.

Publication types

Editorial